Your Catalyst To a Lucrative Business
The worldwide peptide therapeutics market is categorized on the basis of technologies , applications , routes of administration , products , and regions . Based on technologies , the segments are HP PS ( hybrid phase peptide synthesis ), LPPS ( liquid phase peptide synthesis ), and SPPS ( solid phase peptide synthesis ). Owing to cost effectiveness and user-friendliness , SPPS was the largest contributor to the overall industry in 2013 . On the basis of applications , the market is divided into respiratory , cancer , anti-infection , pain , metabolic , cardiovascular , dermatology , renal , gastro intestinal , and others . In 2013 , peptide therapeutics were used extensively in cancer treatment . High incidence of cancer cases worldwide is expected to fuel this segment till 2020 . According to routes of administration , the industry is segmented into mucosal , pulmonary , parenteral , oral , and others . “ Others ” includes nasal and intradermal . Parenteral held the highest industry share in 2013 . Based on products , the bifurcations are generic and innovative . Innovative peptides dominated the overall industry in 2013 . As per regions , the global peptide therapeutics market is categorized into Europe , Asia Pacific , North America , and Rest of the World . North America leads the global industry because of high per capita expenditure on healthcare , rising income levels , and improvements in healthcare infrastructure . The region receives substantial support from the government and also from a number of NGOs . Asia Pacific may witness robust growth over the forecast period because of economic progress , favorable government initiatives , and growing population . Japan , China , and India are the three key regional drivers of the Asia Pacific market . Prominent companies operating in the global peptide therapeutics market are Eli Lilly and Company ; Takeda Pharmaceutical Company Ltd .; Amylin Pharmaceuticals LLC ; Bachem Holding AG ; and Teva Pharmaceuticals . Rhythm , a U . S . based biopharmaceutical company dealing in peptide therapeutics presented the phase 2 clinical trial assessment of setmelanotide in November 2016 . Setmelanotide , a peptide drug , is the company ’ s melanocortin-4 receptor agonist that is generally used to treat LepR ( leptin receptor ) deficiency obesity . This is a rare genetic anomaly that leads to unrelenting hyperphagia and severe obesity . According to the company , this disorder affects nearly two thousand people in the U . S . on an annual basis . Caused by deficiencies & defects in the MC4 pathway , LepR deficiency obesity affects people in their early childhood . The MC4 pathway in humans regulates appetite , energy expenditure , and homeostasis . Setmelanotide ’ s efficacy was tested by researchers when it was administered everyday by subcutaneous injection . Over a period of 22 weeks , a LepR patient lost weight by almost 20 %.
Browse Related Category Market Reports @ https :// www . hexaresearch . com / research-category / clinicaldiagnostics-industry
Follow Us :